ValuEngine upgraded shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a buy rating to a strong-buy rating in a research note published on Friday.

SCMP has been the subject of several other reports. Zacks Investment Research raised Sucampo Pharmaceuticals from a hold rating to a buy rating and set a $11.00 price objective for the company in a research note on Tuesday, October 17th. Mizuho increased their target price on Sucampo Pharmaceuticals from $12.00 to $14.00 and gave the stock a neutral rating in a research note on Friday, December 8th. Nomura initiated coverage on Sucampo Pharmaceuticals in a research note on Monday, December 18th. They set a buy rating and a $43.00 target price for the company. UBS Group cut their target price on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating for the company in a research note on Thursday, October 12th. Finally, BidaskClub raised Sucampo Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, December 5th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $20.25.

Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) opened at $17.95 on Friday. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. The company has a market capitalization of $846.67, a P/E ratio of -5.46, a price-to-earnings-growth ratio of 5.04 and a beta of 1.38. Sucampo Pharmaceuticals has a one year low of $9.30 and a one year high of $18.75.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.30 EPS. equities research analysts predict that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.

In related news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.13% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. purchased a new position in Sucampo Pharmaceuticals in the 2nd quarter valued at approximately $117,000. Trexquant Investment LP purchased a new position in Sucampo Pharmaceuticals in the 3rd quarter valued at approximately $122,000. Nine Chapters Capital Management LLC purchased a new position in Sucampo Pharmaceuticals in the 3rd quarter valued at approximately $127,000. Stifel Financial Corp purchased a new position in Sucampo Pharmaceuticals in the 2nd quarter valued at approximately $131,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Sucampo Pharmaceuticals in the 2nd quarter valued at approximately $132,000. 65.16% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “ValuEngine Upgrades Sucampo Pharmaceuticals (SCMP) to “Strong-Buy”” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/02/05/valuengine-upgrades-sucampo-pharmaceuticals-scmp-to-strong-buy.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.